her 2 the making of herceptin a revolutionary trea
al Trials and FDA Approval The pivotal clinical trials demonstrated that adding Herceptin to standard chemotherapy significantly improved survival rates in HER2-positive breast cancer patients. In 1998, the U.S. Fo
